A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)-Reference-Cited by-同舟云学术

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)

Published:2024-01 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Tombal Bertrand F.^ORCID,Gomez-Veiga Francisco,Gomez-Ferrer Alvaro,López-Campos Fernando,Ost Piet,Roumeguere Thierry Andre,Herrera-Imbroda Bernardo,D'Hondt Lionel A.,Quivrin Magali,Gontero Paolo,Villà Salvador,Khaled Hussein,Fournier Beatrice,Musoro Jammbe,Krzystyniak Joanna,Pretzenbacher Yassin,Loriot Yohann

Publisher

Elsevier BV

Reference25 articles.

1. EAU guidelines. Presented at the EAU Annual Congress Milan 2023;European Association of Urology,2023

2. Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022;Gillessen;Eur Urol,2023

3. Randomized, open-label phase 2 study of apalutamide plus androgen deprivation therapy versus apalutamide monotherapy versus androgen deprivation monotherapy in patients with biochemically recurrent prostate cancer;Aggarwal;Prostate Cancer,2022

4. Long-term antitumor activity and safety of enzalutamide monotherapy in hormone naive prostate cancer: 3-year open label followup results;Tombal;J Urol,2018

5. Long-term efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer: 1- and 2-year open-label follow-up results;Tombal;Eur Urol,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The testosterone replacement therapy for prostate cancer patients: Time to take the leap?;Andrology;2024-05-09